Methods for detecting the efficacy of anticancer treatments
View Patent ↗Methods for determining the effectiveness of anticancer agents by determining and comparing growth factor receptor phosphorylation levels in samples obtained by non-invasive procedures before and after anticancer treatments are provided. The invention also provides methods for detecting growth factor receptor phosphorylation in hair follicles and other tissues obtained by non-invasive means.
1. A method for determining the effectiveness of a cancer treatment comprising:
(a) obtaining non-tumor skin, mucosal or hair follicle tissue samples by non-invasive procedures from a patient before and after a patient undergoes cancer treatment with a chemotherapeutic agent, wherein i) said cancer overexpress epidermal growth factor receptor, ii) said cancer treatment is directed to said growth factor receptor, and iii) said chemotherapeutic agent is a protein kinase inhibitor that reduces phosphorylation of said growth factor receptor;
(b) determining growth factor receptor phosphorylation in said tissues; and
(c) comparing the growth factor receptor phosphorylation in the tissue obtained before treatment to the growth factor receptor phosphorylation in the tissue obtained after treatment, wherein a reduction of growth factor receptor phosphorylation in the tissue obtained after treatment as compared to that in the tissue obtained before treatment is indicative of the effectiveness of the cancer treatment.
2. The method of claim 1 , wherein said tissue sample is a hair follicle.
3. The method of claim 1 , wherein said tissue sample comprises buccal mucosa tissue.
4. The method of claim 1 , wherein said tissue sample comprises a pap-smear sample.
5. The method of claim 1 , wherein said tissue sample comprises bladder-wash cells.
6. The method of claim 1 , wherein said tissue sample comprises skin scrapings.
7. The method of claim 1 , wherein determining growth factor receptor phosphorylation comprises:
(a) contacting the samples with an anti-phosphorylated growth factor receptor antibody;
(b) detecting the bound antibody.
8. The method of claim 7 , wherein the antibody further comprises a detectable label.
9. The method of claim 7 , wherein the bound antibody is detected with a second antibody that comprises a detectable table.
10. The method of claims 8 or 9 wherein the detectable label is selected from a group comprising a fluor, an enzyme, or a radionuclide.
11. The method of claim 7 wherein said detecting comprises immunoflourescence.
12. The method of claim 7 , wherein said detecting comprises colorimetric detection.
13. The method of claim 1 , wherein the patient has cancer of the breast, prostrate, colon, pancreas, head and neck, bladder, blood, bone, bone marrow, esophagus, gastrointestine, brain, kidney, liver, lung, nasopharynx, ovary, skin, stomach, or uterus.
14. The method of claim 1 , wherein said protein kinase inhibitor is a tyrosine kinase inhibitor.
15. The method of claim 14 , wherein said chemotherapeutic agent is PKI166.
16. The method of claim 15 , wherein said chemotherapeutic agent is the C225 antibody.